CA2219280A1 - Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers - Google Patents

Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers

Info

Publication number
CA2219280A1
CA2219280A1 CA002219280A CA2219280A CA2219280A1 CA 2219280 A1 CA2219280 A1 CA 2219280A1 CA 002219280 A CA002219280 A CA 002219280A CA 2219280 A CA2219280 A CA 2219280A CA 2219280 A1 CA2219280 A1 CA 2219280A1
Authority
CA
Canada
Prior art keywords
potassium channel
mammalian eye
channel blockers
administration
intraocular pressure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002219280A
Other languages
French (fr)
Other versions
CA2219280C (en
Inventor
Joseph S. Adorante
Elizabeth Woldemussie
Guadalupe Ruiz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan
Joseph S. Adorante
Elizabeth Woldemussie
Guadalupe Ruiz
Allergan Sales, Inc.
Allergan Sales, Llc
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/431,170 external-priority patent/US5573758A/en
Application filed by Allergan, Joseph S. Adorante, Elizabeth Woldemussie, Guadalupe Ruiz, Allergan Sales, Inc., Allergan Sales, Llc, Allergan, Inc. filed Critical Allergan
Publication of CA2219280A1 publication Critical patent/CA2219280A1/en
Application granted granted Critical
Publication of CA2219280C publication Critical patent/CA2219280C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Pharmaceutical compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains, as the active ingredient, one or more compounds having potassium channel blocking activity. Examples of potassium channel blockers utilized in the pharmaceutical composition and method of treatment are quinine, tremogenic indole alkaloids, such as Penitrem A and paspalicine, and insect toxins such i as charybdotoxin and iberiotoxin.
CA002219280A 1995-04-28 1996-04-16 Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers Expired - Fee Related CA2219280C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/431,170 1995-04-28
US08/431,170 US5573758A (en) 1995-04-28 1995-04-28 Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
PCT/US1996/005241 WO1996033719A1 (en) 1995-04-28 1996-04-16 Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers

Publications (2)

Publication Number Publication Date
CA2219280A1 true CA2219280A1 (en) 1996-10-31
CA2219280C CA2219280C (en) 2007-03-13

Family

ID=38008003

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002219280A Expired - Fee Related CA2219280C (en) 1995-04-28 1996-04-16 Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers

Country Status (1)

Country Link
CA (1) CA2219280C (en)

Also Published As

Publication number Publication date
CA2219280C (en) 2007-03-13

Similar Documents

Publication Publication Date Title
ES2182973T3 (en) METHOD FOR REDUCING INTRAOCULAR PRESSURE IN THE MAMMAL EYE BY ADMINISTRATION OF POTASSIUM CHANNEL BLOCKERS.
EP1225168B8 (en) Prostaglandin-F-2 alpha derivative for the treatment of glaucoma or ocular hypertension
LU90969I2 (en) Topical ophthalmic compositions containing olopatadine for the treatment of allergic eye conditions
EP1514548A3 (en) Use of cloprostenol fluprostenol, and their analogues to treat glaucoma and ocular hypertension
MX9702349A (en) Use of 9-deoxy prostaglandin derivatives to treat glaucoma.
IE811654L (en) Ophthalmic composition
AU5446299A (en) Medicinal compositions for treating eye diseases
WO2002009702A3 (en) Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
EP0366279A3 (en) Ocular hypotensive agents
CA2190303A1 (en) Pharmaceutical composition, method and device for preventing or treating dry eye or disease caused therefrom
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
AU687906B2 (en) Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
WO1995034302A3 (en) Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators
EP0911027A4 (en) Peripheral circulation improvers for ophthalmic tissues containing dihydropyridines
CA2125056A1 (en) Ophthalmic topical composition
EP0842663A4 (en) Ophthalmic preparations
CA2219280A1 (en) Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
EP0345028A3 (en) Treatment of glaucoma using phosphodiesterase inhibitor
WO2003011299A3 (en) Treatment of ocular hypertension and glaucoma
AU7587396A (en) Ocular depressor
RU97118811A (en) METHOD FOR TREATING PRIMARY OPEN-ANGLE GLAUCOMA

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140416